Lucia Lintnerova

Dr. Lucia Lintnerova

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JVJindra Valentova
Jindra Valentova
LLLucia Lintnerova
Lucia Lintnerova
Natalia MiklášováNatalia Miklášová
Natalia Miklášová
BOBianka Obonova
Bianka Obonova
LHLadislav Habala
Ladislav Habala
Life is chiral, as its constituents consist, to a large degree, of optically active molecules, be they macromolecules (proteins, nucleic acids) or small biomolecules. Hence, these molecules interact disparately with different enantiomers of chiral compounds, creating a preference for a particular enantiomer. This chiral discrimination is of special importance in medicinal chemistry, since many pharmacologically active compounds are used as racemates—equimolar mixtures of two enantiomers. Each of these enantiomers may express different behaviour in terms of pharmacodynamics, pharmacokinetics, and toxicity. The application of only one enantiomer may improve the bioactivity of a drug, as well as reduce the incidence and intensity of adverse effects. This is of special significance regarding the structure of natural products since the great majority of these compounds contain one or several chiral centres. In the present survey, we discuss the impact of chirality on anticancer chemotherapy and highlight the recent developments in this area. Particular attention has been given to synthetic derivatives of drugs of natural origin, as naturally occurring compounds constitute a major pool of new pharmacological leads. Studies have been selected which report the differential activity of the enantiomers or the activities of a single enantiomer and the racemate.

14 February 2018 in Monatshefte für Chemie - Chemical Monthly
Verified
Journal Article
Closed access
PDF file
LLLucia Lintnerova
Lucia Lintnerova
JVJindra Valentová
Jindra Valentová
PHPeter Herich
Peter Herich
JKJozef Kožíšek
Jozef Kožíšek
FDFerdinand Devínsky
Ferdinand Devínsky

22 August 2025 in Molecules
Verified
Journal Article
Open access
LLLucia Lintnerova
Lucia Lintnerova
PHPeter Herich
Peter Herich
JKJana Korcová
Jana Korcová
BSBarbora Svitková
Barbora Svitková
FJFlóra Jozefíková
Flóra Jozefíková
JVJindra Valentova
Jindra Valentova
Schiff base ligands prepared from salicylaldehyde and 2-, 3- and 4-methoxybenzylamine were used to prepare copper(II) complexes, characterized by spectral methods, elemental analysis and X-ray crystallography in the case of complex 4a derived from 2-methoxybenzylamine. The DNA cleavage activity of the prepared complexes was exceptional, with best activities of over 95% one-strand cleavage for 4c at 3 mM and full double-strand cleavage for complex 4a at 5 mM. Absorption titration studies with ct-DNA revealed good binding constants (at 105 M−1) with a decrease of up to 56% light absorption. Meanwhile, the EB–DNA displacement method and viscosity studies revealed groove binding as a possible binding mode. For BSA binding studies, all three complexes showed KBSA values in the optimal range for reversible BSA binding (104 M−1). The copper(II) complexes showed significant cytotoxic effects (67–96% at 1 mM) in mitochondrial activity monitoring assays. Cytotoxicity was confirmed against cancer cell lines (A549 and HepG2) and HEL cells. The complexes 4a and 4c exhibited high activity against HepG2 cancer cells (IC50 < 22 μM), comparable to cisplatin. The radical scavenging activity was determined by the INT method with the best IC50 for 4c (189 ± 11 μM). Overall, complexes 4a and 4c with a methoxy group in the ortho and para positions show high potential in most determined activities, but mainly as DNA cleavers and as cytotoxic agents with selectivity against HepG2 cells.

1 September 2021
Verified
Book Chapter
Open access
PDF file
JVJindra Valentova
Jindra Valentova
LLLucia Lintnerova
Lucia Lintnerova
Many drugs are chiral and their therapeutic activity depends on specific recognition of chiral biomolecules. The biological activity of enantiomers can also differ drastically in terms of toxicity and pharmacokinetics. Chiral natural biological molecules, such as nucleic acids, enzymes are targeted molecules for the development of anticancer drugs. The interest in chiral agents is logically a result of the different interaction with biomolecules leading in the end consequence to improve anticancer activity and maybe to less undesirable effects. This review outlines the effects of chirality on the efficiency of anticancer metal-based agents and potential organic drugs. A variety of up-to-date examples of structurally diverse chiral agents exhibiting different mechanisms in their antitumor activity is presented.

Verified
Journal Article
Open access
PDF file
LLLucia Lintnerova
Lucia Lintnerova
PHPeter Herich
Peter Herich
JKJana Korec
Jana Korec
BSBarbora Svitková
Barbora Svitková
FJFlóra Jozefíková
Flóra Jozefíková
JVJindra Valentova
Jindra Valentova
A series of reduced Schiff base ligands derived from salicylaldehyde (1) and methoxybenzylamines (2a–c) were prepared and used to prepare three copper(II) complexes, 5a (2-methoxyderivative), 5b (3-methoxyderivative), and 5c (4-methoxyderivative). They were characterized by spectral methods and X-ray crystallography. The complexes showed DNA cleavage activity, with 30% cleavage at 3 × 10−3 M and up to 94.5% at 5 × 10−3 M. Absorption titration studies with ct-DNA and EB-DNA displacement methods revealed strong binding of the prepared complexes, with complexes 5b and 5c favored. Viscosity measurements and thermal degradation of DNA studies indicate DNA groove binding. All complexes exhibit a moderately strong binding affinity to serum albumin. The complexes performed very well in the resazurin assay monitoring mitochondrial activity, with significant cytotoxic effects (around 95% already at 1 × 10−4 M). The MTT assay confirmed the complexes’ cytotoxicity against cancer cell lines (A549, HepG2) compared with HEL fibroblasts. All complexes showed remarkable selectivity for HepG2 cells, with selectivity indices (HEL vs. HepG2) up to 3.05 for complex 5a, and complex 5b achieved the lowest IC50 (33.0 ± 5.3 μM) against HepG2 cells. From a regioisomerism perspective, complex 5a outperformed the others in DNA cleavage; complex 5b, with the 3-methoxy group, showed the most interesting cytotoxicity results, and both complexes 5b and 5c showed good DNA-binding properties.